Luís Fonseca

Dr. Luís Fonseca

University of Lisbon - Instituto Superior Técnico
+1
orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2008 in Talanta
Verified
Journal Article
Closed access
FTF Teles
F Teles
Luís FonsecaLuís Fonseca
Luís Fonseca

24 April 2019 in Antibiotics
Verified
Journal Article
Open access
PDF file
BCBernardo Ribeiro da Cunha
Bernardo Ribeiro da Cunha
Luís FonsecaLuís Fonseca
Luís Fonseca
Cecília CaladoCecília Calado
Cecília Calado
Given the increase in antibiotic-resistant bacteria, alongside the alarmingly low rate of newly approved antibiotics for clinical usage, we are on the verge of not having effective treatments for many common infectious diseases. Historically, antibiotic discovery has been crucial in outpacing resistance and success is closely related to systematic procedures—platforms—that have catalyzed the antibiotic golden age, namely the Waksman platform, followed by the platforms of semi-synthesis and fully synthetic antibiotics. Said platforms resulted in the major antibiotic classes: aminoglycosides, amphenicols, ansamycins, beta-lactams, lipopeptides, diaminopyrimidines, fosfomycins, imidazoles, macrolides, oxazolidinones, streptogramins, polymyxins, sulphonamides, glycopeptides, quinolones and tetracyclines. During the genomics era came the target-based platform, mostly considered a failure due to limitations in translating drugs to the clinic. Therefore, cell-based platforms were re-instituted, and are still of the utmost importance in the fight against infectious diseases. Although the antibiotic pipeline is still lackluster, especially of new classes and novel mechanisms of action, in the post-genomic era, there is an increasingly large set of information available on microbial metabolism. The translation of such knowledge into novel platforms will hopefully result in the discovery of new and better therapeutics, which can sway the war on infectious diseases back in our favor.

1 December 2008 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
FTF.R.R. Teles
F.R.R. Teles
Luís FonsecaLuís Fonseca
Luís Fonseca

1 January 2003
Verified
Book Chapter
Closed access
AAAna Azevedo
Ana Azevedo
VRVerónica C. Martins Romão
Verónica C. Martins Romão
Duarte Miguel PrazeresDuarte Miguel Prazeres
Duarte Miguel Prazeres
VVVojislav Vojinović
Vojislav Vojinović
Joaquim M.S. CabralJoaquim M.S. Cabral
Joaquim M.S. Cabral
Luís FonsecaLuís Fonseca
Luís Fonseca

1 August 2005 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
AAAna Azevedo
Ana Azevedo
Duarte Miguel PrazeresDuarte Miguel Prazeres
Duarte Miguel Prazeres
Joaquim M.S. CabralJoaquim M.S. Cabral
Joaquim M.S. Cabral
Luís FonsecaLuís Fonseca
Luís Fonseca

1 April 2006 in Sensors and Actuators B: Chemical
Verified
Journal Article
Closed access
VVV. Vojinović
V. Vojinović
Joaquim M.S. CabralJoaquim M.S. Cabral
Joaquim M.S. Cabral
Luís FonsecaLuís Fonseca
Luís Fonseca